Current treatment for heart failure with reduced ejection fraction. A systematic review of the new therapies

• Published in: AMC. Acta médica Colombiana 2021-12, Vol.46 (4), p.26-42
• Main Authors: GÁNDARA-RICARDO, JAIRO ALFONSO, MUÑOZ-ORTIZ, EDISON, AGUILAR-MOLINA, OSWALDO ENRIQUE, GARCÍA-RUEDA, KAREN, GIRALDO-RAMÍREZ, SANTIAGO, SALAMANCA-MONTILLA, JHON FREDY, SÉNIOR-SÁNCHEZ, JUAN MANUEL
• Format: Article
• Language: Portuguese
• Subjects: MEDICINE, GENERAL & INTERNAL
• ISSN: 0120-2448
• DOI: 10.36104/amc.2021.2108

Abstract Introduction: heart failure with reduced ejection fraction has a growing therapeutic arsenal. Thus, the indications for each therapy must be refined. Methods: a systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, to update the systematic search performed in the development of the "Clinical Practice Guidelines for Prevention, Diagnosis, Treatment and Rehabilitation" (CPG) of the Colombian Ministry of Health. Results: six new clinical trials were found which substantially modify the main recommendations of the CPG. Angiotensin receptor antagonists combined with neprilysin inhibitors (ARNI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, betablockers and mineralocorticoid receptor antagonists (MRA) are now the main core of treatment for patients with heart failure with reduced ejection fraction. Other therapeutic options should be considered after beginning and titrating the doses of these four medications. Discussion: given the robustness of the evaluating studies, the proposed practical scheme, as the central core with four fundamental therapeutic strategies, will improve the treatment of patients with heart failure and allow the stepwise inclusion of other alternatives, plotted as orbits, to impact on other individual outcomes. (Acta Med Colomb 2021; 46. DOI: https://doi.org/10.36104/amc.2021.2108).